Mortality and Attrition Rates within the First Year of Antiretroviral Therapy Initiation among People Living with HIV in Guangxi, China: An Observational Cohort Study

Table 4

Attrition rate of the first year in PLHIV who started ART between 2003 and June 2015 in Guangxi, China.

Variable	Number	Attritions	Person-years	Attritions per 100 person-years (95% CI)	HR (95% CI)		AHR (95% CI)
Total	58,115	8,947	51,066.90	17.52 (17.17-17.87)	—	—	—	—
Age (years)
18-34	18,358	2,424	16,591.47	14.61 (14.04-15.18)	Reference		Reference
35-49	19,290	2,770	17,079.86	16.22 (15.63-16.81)	1.11 (1.05-1.17)	<0.001	1.15 (1.09-1.22)	<0.001
50-70	17,457	2,958	15,016.71	19.7 (19.01-20.39)	1.35 (1.28-1.42)	<0.001	1.55 (1.46-1.64)	<0.001
≥70	3,010	795	2,378.87	33.42 (31.15-35.68)	2.27 (2.09-2.46)	<0.001	2.51 (2.30-2.73)	<0.001
Sex
Male	38,957	6,284	33,799.71	18.59 (18.14-19.04)	Reference		Reference
Female	19,158	2,663	17,267.19	15.42 (14.85-15.99)	0.83 (0.79-0.87)	<0.001	0.89 (0.85-0.94)	<0.001
Marital status
Married or cohabitation	40,224	5,697	35,698.49	15.96 (15.55-16.36)	Reference		Reference
Other	17,891	3,250	15,368.41	21.15 (20.44-21.86)	1.32 (1.27-1.38)	<0.001	1.32 (1.26-1.38)	<0.001
Route of HIV transmission
Heterosexual intercourse	49,608	7,357	43,780.65	16.80 (16.43-17.18)	Reference		Reference
Intravenous drug use	5,954	1,289	4,994.46	25.81 (24.43-27.18)	1.53 (1.44-1.62)	<0.001	1.87 (1.75-2.00)	<0.001
Homosexual intercourse	925	66	866.24	7.62 (5.83-9.41)	0.45 (0.36-0.58)	<0.001	0.45 (0.35-0.58)	<0.001
Other	1,628	235	1,425.56	16.48 (14.43-18.54)	0.98 (0.86-1.12)	0.783	1.08 (0.95-1.23)	0.226
CD4 cell count (cells/μL) before ART
<200	34,774	5,030	30,201.91	16.65 (16.21-17.10)	Reference		Reference
200-350	16,252	2,598	14,605.50	17.79 (17.12-18.45)	1.07 (1.02-1.12)	0.006	1.01 (0.96-1.06)	0.765
350-500	4,550	783	4,076.29	19.21 (17.90-20.52)	1.15 (1.07-1.24)	<0.001	1.11 (1.03-1.21)	0.007
≥500	1,648	321	1,459.20	22.00 (19.65-24.34)	1.32 (1.18-1.48)	<0.001	1.29 (1.15-1.45)	<0.001
Missing	891	215	724.00	29.70 (25.83-33.57)	1.78 (1.55-2.04)	<0.001	1.62 (1.41-1.86)	<0.001
Initial ART regimen
The first-line ART containing D4T	14,244	1,922	12,276.66	15.66 (14.97-16.34)	Reference		Reference
The first-line ART containing AZT	23,059	3,845	20,389.98	18.86 (18.28-19.44)	1.20 (1.14-1.27)	<0.001	1.09 (1.03-1.16)	0.003
The first-line ART containing TDF	13,965	1,935	12,508.72	15.47 (14.80-16.14)	0.99 (0.93-1.05)	0.734	0.81 (0.75-0.87)	<0.001
The first-line ART containing LPV/r	4,510	1,004	3,765.83	26.66 (25.05-28.27)	1.70 (1.57-1.83)	<0.001	1.34 (1.23-1.46)	<0.001
Other	2,337	241	2,125.71	11.34 (9.94-12.73)	0.73 (0.64-0.83)	<0.001	0.87 (0.76-1.00)	0.044
Level of ART site
Provincial	10,920	1,470	9,810.33	14.98 (14.24-15.73)	Reference		Reference
Prefecture	22,525	3,378	20,001.78	16.89 (16.33-17.44)	1.13 (1.06-1.20)	<0.001	1.02 (0.96-1.08)	0.593
County	24,670	4,099	21,254.79	19.29 (18.71-19.86)	1.29 (1.21-1.36)	<0.001	1.04 (0.98-1.11)	0.178
Year of ART initiation
2003-2008	7,741	694	6,865.09	10.11 (9.38-10.84)	Reference		Reference
2009-2011	17,800	2,813	15,542.50	18.1 (17.45-18.75)	1.78 (1.64-1.93)	<0.001	1.74 (1.60-1.91)	<0.001
2012-2015	32,574	5,440	28,659.32	18.98 (18.49-19.47)	1.87 (1.73-2.02)	<0.001	1.90 (1.73-2.08)	<0.001

ART: antiretroviral therapy; D4T: stavudine; AZT: azidothymidine; TDF: tenofovir; LPV/r: ritonavir-boosted lopinavir; HR: hazard ratio; AHR: adjusted hazard ratio.